Xilio Therapeutics (XLO) Capital Expenditures (2020 - 2026)
Xilio Therapeutics (XLO) reported Capital Expenditures of $556000.0 for Q1 2026, up 90.41% on a YoY basis from $292000.0 in Q1 2025, and up 2680.0% sequentially from $20000.0 in Q4 2025.
Xilio Therapeutics (XLO) Capital Expenditures (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Capital Expenditures data on file, last reported at $556000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 90.41% year-over-year to $556000.0; the trailing twelve-month figure through Mar 2026 stood at $707000.0 (up 130.29% YoY), and the FY2025 full-year result was $443000.0, up 1130.56% from the prior year.
- Capital Expenditures grew to $556000.0 in Q1 2026, from $20000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $771000.0 in Q2 2022 to a low of -$1.3 million in Q4 2022.
- A 5-year average of $118461.5 and a median of $170000.0 in 2023 frame the typical range for Capital Expenditures.
- Across the five-year window, Capital Expenditures slumped 372.15% in 2022 and surged 1290.48% in 2025, its largest moves.
- Tracing XLO's Capital Expenditures over 5 years: stood at -$1.3 million in 2022, then jumped by 123.6% to $316000.0 in 2023, then slumped by 98.1% to $6000.0 in 2024, then soared by 233.33% to $20000.0 in 2025, then surged by 2680.0% to $556000.0 in 2026.
- Business Quant data shows XLO's Capital Expenditures at $556000.0 in Q1 2026, $20000.0 in Q4 2025, and $131000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 786,000.00 |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | 556,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 556,000.00 |
| Mar 31, 2026 | 556,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 292,000.00 |
| Mar 31, 2025 | 292,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Jun 30, 2023 | 316,000.00 |
| Jun 30, 2023 | 316,000.00 |
| Mar 31, 2023 | 170,000.00 |
| Mar 31, 2023 | 170,000.00 |
| Dec 31, 2022 | -1.34 Mn |
| Dec 31, 2022 | -1.34 Mn |